Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Background Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion f...

Full description

Saved in:
Bibliographic Details
Main Authors: Dirk Schadendorf, Lucie Heinzerling, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Elisabeth Livingstone, Selma Ugurel, Ulrike Keim, Claus Garbe, Valerie Glutsch, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Katharina Kaehler, Sebastian Haferkamp, David Rafei-Shamsabadi, Lydia Reinhardt, Claudia Pfoehler, Carmen Loquai, Michael Weichenthal, Jürgen Christian Becker, Ulrike Leiter, Judith Sirokay, Nora Schlecht, Albert Rübben, Kerstin Schatton, Cindy Franklin, Lena Bischof, Andreas Meiwes
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000897.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e000897.full

Similar Items